Table 1.
Description of the three study populations used for each of the three respective stages of the analysis.
| TCGA (tumor)
|
CoHANDs (oral rinse)
|
pdifference | ||
|---|---|---|---|---|
| Discovery (n = 88) | Replication (n = 82) | Validation (n = 61) | ||
| Age, median years (range) | 61.0 (19-90) | 58.0 (23-85) | 61.0 (23-88) | 0.17‡ |
| Gender, n (%) | ||||
| Female | 28 (31.8%) | 36 (43.9%) | 24 (39.3%) | 0.26§ |
| Male | 60 (68.2%) | 46 (56.1%) | 37 (60.7%) | |
| Race, n (%) | ||||
| White | 85 (96.6%) | 79 (96.3%) | 52 (85.3%) | 0.02§ |
| Other | 3 (3.4%) | 3 (3.7%) | 9 (14.8%) | |
| Smoking status, n (%) | ||||
| Never | 19 (21.6%) | 30 (36.6%) | 20 (32.8%) | 0.01§ |
| Former | 42 (47.7%) | 36 (43.9%) | 28 (45.9%) | |
| Current | 25 (28.4%) | 8 (9.8%) | 5 (8.2%) | |
| Missing | 2 (2.3%) | 8 (9.8%) | 8 (13.1%) | |
| Smoking pack-years*, median (range) | 40.0 (1.0-300.0) | 21.9 (0.9-102.5) | 31.5 (0.5-129.0) | 0.03‡ |
| Alcohol consumption, n (%) | ||||
| None | 3 (3.4%) | 7 (8.5%) | 7 (11.5%) | 0.22§ |
| ≤ 2 drinks per day | 11 (12.5%) | 46 (56.1%) | 27 (44.3%) | |
| > 2 drinks per day | 14 (15.9%) | 20 (24.4%) | 19 (31.2%) | |
| Missing | 60 (68.2%) | 9 (11.0%) | 8 (13.1%) | |
| HPV16 serology†, n (%) | ||||
| Negative | --- | 64 (78.0%) | 32 (52.5%) | 0.50§ |
| Positive | --- | 9 (11.0%) | 2 (3.3%) | |
| Missing | --- | 9 (11.0%) | 27 (44.3%) | |
| Stage at diagnosis, n (%) | ||||
| Local (stage I or II) | 15 (17.0%) | 48 (58.5%) | 29 (47.5%) | < 0.001§ |
| Advanced (III or IV) | 69 (78.4%) | 34 (41.5%) | 29 (47.5%) | |
| Missing | 4 (4.5%) | 0 (0.0%) | 3 (4.9%) | |
*
Ever-smokers only (i.e. former or current). Pack-year data is missing for 24 Discovery subjects, 8 Replication subjects, and 8 Validation subjects
†
Based on HPV16 E6 or E7 serology; no HPV serology was available for the TCGA samples (14 had HPV immunohistochemistry results available, all of which were negative)
‡
Kruskal-Wallis equality-of-populations rank test
§
Fisher’s exact test for non-missing values